[go: up one dir, main page]

HK1149011A1 - Triazolopyridazines as par1 inhibitors, production thereof, and use for producing medicaments - Google Patents

Triazolopyridazines as par1 inhibitors, production thereof, and use for producing medicaments

Info

Publication number
HK1149011A1
HK1149011A1 HK11103239.2A HK11103239A HK1149011A1 HK 1149011 A1 HK1149011 A1 HK 1149011A1 HK 11103239 A HK11103239 A HK 11103239A HK 1149011 A1 HK1149011 A1 HK 1149011A1
Authority
HK
Hong Kong
Prior art keywords
triazolopyridazines
production
producing medicaments
par1 inhibitors
par1
Prior art date
Application number
HK11103239.2A
Other languages
English (en)
Inventor
Uwe Heinelt
Volkmar Wehner
Matthias Herrmann
Karl Schoenafinger
Henning Steinhagen
Bodo Scheiper
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of HK1149011A1 publication Critical patent/HK1149011A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK11103239.2A 2008-02-05 2011-03-30 Triazolopyridazines as par1 inhibitors, production thereof, and use for producing medicaments HK1149011A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08290112 2008-02-05
PCT/EP2009/000406 WO2009097970A1 (de) 2008-02-05 2009-01-23 Triazolopyridazine als par1-inhibitoren, ihre herstellung und verwendung als arzneimittel

Publications (1)

Publication Number Publication Date
HK1149011A1 true HK1149011A1 (en) 2011-09-23

Family

ID=39539711

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11103239.2A HK1149011A1 (en) 2008-02-05 2011-03-30 Triazolopyridazines as par1 inhibitors, production thereof, and use for producing medicaments

Country Status (32)

Country Link
US (2) US8076336B2 (xx)
EP (1) EP2240487B1 (xx)
JP (1) JP5526040B2 (xx)
KR (1) KR20100114514A (xx)
CN (1) CN101981034B (xx)
AR (1) AR070410A1 (xx)
AT (1) ATE537172T1 (xx)
AU (1) AU2009211887B2 (xx)
BR (1) BRPI0907486A2 (xx)
CA (1) CA2713550C (xx)
CL (1) CL2009000236A1 (xx)
CO (1) CO6260083A2 (xx)
CY (1) CY1113228T1 (xx)
DK (1) DK2240487T3 (xx)
ES (1) ES2379447T3 (xx)
HK (1) HK1149011A1 (xx)
HR (1) HRP20120230T1 (xx)
IL (1) IL207205A0 (xx)
MA (1) MA32061B1 (xx)
MX (1) MX2010008490A (xx)
MY (1) MY152040A (xx)
NZ (1) NZ587141A (xx)
PA (1) PA8814801A1 (xx)
PE (1) PE20091455A1 (xx)
PL (1) PL2240487T3 (xx)
PT (1) PT2240487E (xx)
RS (1) RS52264B (xx)
RU (1) RU2499797C2 (xx)
SI (1) SI2240487T1 (xx)
TW (1) TW200946532A (xx)
WO (1) WO2009097970A1 (xx)
ZA (1) ZA201004467B (xx)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009002842A (es) * 2006-09-18 2009-05-27 Vertex Pharma Inhibidores heterociclicos de c-met y usos de los mismos.
PL2240486T3 (pl) * 2008-02-05 2016-02-29 Sanofi Sa Sole triazoliowe jako inhibitory PAR1, ich wytwarzanie i zastosowanie jako lek
US8673890B2 (en) 2009-10-29 2014-03-18 Janssen Pharmaceutica Nv 2,3-dihydro-1H-isoindol-1-imine derivatives useful as thrombin PAR-1 receptor antagonist
WO2020254554A1 (en) * 2019-06-19 2020-12-24 Nmd Pharma A/S Process for the preparation of clc-1 chloride channel inhibitors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4578464A (en) 1983-11-22 1986-03-25 Merrell Dow Pharmaceuticals Inc. 6-Hydroxyalkylamino-8-methyl-1,2,4-triazolo-[4,3-b]pyridazine and related compounds
WO1996008496A1 (en) * 1994-09-16 1996-03-21 Takeda Chemical Industries, Ltd. Triazolopyridazines process and intermediates for their preparation and their use as medicaments
US6063847A (en) 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
US7488742B2 (en) 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
JP4220249B2 (ja) 2001-04-19 2009-02-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 サイクリックアミジン誘導体
EP1391452A4 (en) 2001-05-25 2005-10-26 Mochida Pharm Co Ltd 4-HYDROXPIPERIDIN DERIVATIVE ANALGETIC EFFECT
WO2003031442A1 (fr) 2001-10-05 2003-04-17 Takeda Chemical Industries, Ltd. Composes heterocycliques, derives oxazole, procede permettant de les presenter et leur utilisation
PE20030808A1 (es) 2001-10-18 2003-09-22 Schering Corp Derivados triciclicos heterociclicos como antagonistas receptores de trombina
ATE455774T1 (de) 2002-04-16 2010-02-15 Schering Corp Trizyklische thrombinrezeptorantagonisten
WO2004078721A1 (ja) 2003-02-19 2004-09-16 Eisai Co., Ltd. 環状ベンズアミジン誘導体の製造方法
TW200531688A (en) 2004-03-05 2005-10-01 Hoffmann La Roche Novel pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents
EP1813282A4 (en) 2004-11-09 2011-03-02 Eisai R&D Man Co Ltd MEANS FOR THE TREATMENT OF ANGIOSPASM IN SUBARACHO-OAL BLOODING WITH THROMBIN RECEPTOR ANTAGONIST AS AN ACTIVE AGENT
NZ568807A (en) * 2005-12-21 2011-05-27 Janssen Pharmaceutica Nv Triazolopyridazines as tyrosine kinase modulators
DE102006025318A1 (de) * 2006-05-31 2007-12-06 Bayer Healthcare Ag Dihydro-pyrrolopyridin-, Dihydro-pyrrolopyridazin- und Dihydro-pyrrolopyrimidin-Derivate und ihre Verwendung
DE102006036023A1 (de) * 2006-08-02 2008-02-07 Sanofi-Aventis Imino-imidazo-pyridinderivate mit antithrombotischer Aktivität
CA2713554C (en) 2008-02-05 2016-09-06 Sanofi-Aventis Imidazopyridazines as par1 inhibitors, production thereof, and use as medicaments
SI2242740T1 (sl) 2008-02-05 2013-03-29 Sanofi SF5-derivati kot PAR1 inhibitorji, njihova priprava in uporaba kot zdravila
PL2240486T3 (pl) * 2008-02-05 2016-02-29 Sanofi Sa Sole triazoliowe jako inhibitory PAR1, ich wytwarzanie i zastosowanie jako lek
WO2009126624A1 (en) 2008-04-11 2009-10-15 Bristol-Myers Squibb Company Triazolo compounds useful as dgat1 inhibitors
WO2009126861A2 (en) 2008-04-11 2009-10-15 Bristol-Myers Squibb Company Triazolopyridine compounds useful as dgat1 inhibitors

Also Published As

Publication number Publication date
RU2499797C2 (ru) 2013-11-27
CN101981034A (zh) 2011-02-23
TW200946532A (en) 2009-11-16
ATE537172T1 (de) 2011-12-15
PE20091455A1 (es) 2009-10-22
EP2240487A1 (de) 2010-10-20
AU2009211887A1 (en) 2009-08-13
IL207205A0 (en) 2010-12-30
DK2240487T3 (da) 2012-04-02
CL2009000236A1 (es) 2009-06-05
PL2240487T3 (pl) 2012-05-31
MA32061B1 (fr) 2011-02-01
HRP20120230T1 (hr) 2012-04-30
MX2010008490A (es) 2010-08-18
SI2240487T1 (sl) 2012-04-30
US20120010203A1 (en) 2012-01-12
KR20100114514A (ko) 2010-10-25
JP2011511016A (ja) 2011-04-07
US9079906B2 (en) 2015-07-14
US20110034451A1 (en) 2011-02-10
AU2009211887B2 (en) 2013-09-19
EP2240487B1 (de) 2011-12-14
CA2713550A1 (en) 2009-08-13
BRPI0907486A2 (pt) 2015-07-14
MY152040A (en) 2014-08-15
AR070410A1 (es) 2010-04-07
RU2010136957A (ru) 2012-03-20
CY1113228T1 (el) 2016-04-13
CO6260083A2 (es) 2011-03-22
RS52264B (en) 2012-10-31
US8076336B2 (en) 2011-12-13
CA2713550C (en) 2016-06-14
CN101981034B (zh) 2013-08-14
ZA201004467B (en) 2011-09-28
NZ587141A (en) 2012-04-27
PA8814801A1 (es) 2009-09-17
WO2009097970A1 (de) 2009-08-13
ES2379447T3 (es) 2012-04-26
PT2240487E (pt) 2012-03-08
JP5526040B2 (ja) 2014-06-18

Similar Documents

Publication Publication Date Title
IL245050A0 (en) Optimum fc variants, pharmaceutical preparations and drugs containing them, and a method for their preparation
IL211115A0 (en) Novel benzamides, production thereof, and use thereof as medicaments
PT2242740E (pt) Derivados de sf5 como inibidores do par1, sua preparação e utilização como produtos farmacêuticos
ZA201001015B (en) (Carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
ZA201001014B (en) (Cyclopropyl-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
IL219530A (en) Converted 4-aminocyclohexane compounds, drugs containing these compounds and their use in the preparation of drugs
IL193340A0 (en) Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
EP2239054A4 (en) CATALYST, MANUFACTURING METHOD AND USE THEREOF
IL212605A (en) Pyrimidine-4-carboxamide cycles and their use as drugs
IL216826A0 (en) Pyridil-triazine derivatives, compositions comprising the same and processes for producing the same
IL202892A (en) Diphthoid drugs, the process of making and using them to make the resulting drugs and drugs
IL195245A0 (en) Substituted prolinamides, production thereof and their use as drugs
HK1167597A1 (en) Dodeca-2e,4e-diene amides and their use as medicaments and cosmetics -2e4e-
IL210869A (en) Derivatives of imidaziadiazoles, their process, preparation, uses and medications containing them
IL216388A0 (en) New compounds, pharmaceutical composition and methods relating thereto
IL211713A (en) History of Anilinopyrimidine Converted to Sulfoxaamine as CDK Inhibitors, Manufactured and Used as Drugs
IL193341A0 (en) Novel azacyclyl-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments
IL193339A0 (en) Novel aminoalcohol-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
EP2239055A4 (en) CATALYST, MANUFACTURING METHOD AND USE THEREOF
IL215835A (en) Carboxamide compounds and their use as a drug
HK1149012A1 (en) Triazolium salts as par1 inhibitors, production thereof, and use as medicaments
HK1148956A1 (en) Imidazopyridazines as par1 inhibitors, production thereof, and use thereof as medicaments
HK1149011A1 (en) Triazolopyridazines as par1 inhibitors, production thereof, and use for producing medicaments
IL211062A0 (en) Pharmaceutical uses of lanosta-8,24-dien-3-ols
EP2363132A4 (en) USE OF SOPHORICOSIDE IN DRUG MANUFACTURE

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180123